The current status of combination therapy of Chronic Hepatitis B

被引：0
作者：
Chen, E. -Q.
Tang, H. [1 ]
机构：
[1] Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610064, Sichuan Provinc, Peoples R China
来源：
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2013年 / 17卷 / 15期
关键词：
Chronic hepatitis B; Combination therapy; Advantage; Candidates; Strategy; NUCLEOCAPSID PROMOTER VARIANT; PARTIAL VIROLOGICAL RESPONSE; ADEFOVIR DIPIVOXIL THERAPY; NUCLEAR HORMONE RECEPTORS; ANTIGEN-POSITIVE PATIENTS; VIRUS DNA LEVEL; HEPATOCELLULAR-CARCINOMA; LIVER-TRANSPLANTATION; NUCLEOS(T)IDE ANALOGS; POOR RESPONSE;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In the past decade, the treatment of chronic Hepatitis B (CHB) has been revolutionized by the increased availability of effective antiviral agents. However, there is an alarming of the increasing rates of viral resistance and suboptimal response in CHB patients with single drug therapy. Recently, the strategy of combination therapy for CHB has been proposed and concerned by clinicians. In this review, using PubMed and web of science as main searching tools, we evaluated various latest research reports on combination therapy for CHB, and made a summary of the progress of combination antiviral therapy and outline areas that need to be addressed in the future.
引用
收藏
页码：2023 / 2031
页数：9
相关论文
共 84 条
[1]   Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome [J].
Alcantara, FF ;
Tang, H ;
McLachlan, A .
NUCLEIC ACIDS RESEARCH, 2002, 30 (09) :2068-2075
[2]   A Randomized Study of Adefovir Dipivoxil in Place of HBIG in Combination with Lamivudine As Post-Liver Transplantation Hepatitis B Prophylaxis [J].
Angus, Peter W. ;
Patterson, Scott J. ;
Strasser, Simone J. ;
McCaughan, Geoffrey W. ;
Gane, Edward .
HEPATOLOGY, 2008, 48 (05) :1460-1466
[3]  
[Anonymous], P CSEE
[4]  
Bennett J.C., 1996, Cecil textbook of medicine
[5]   Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B [J].
Bonino, F. ;
Marcellin, P. ;
Lau, G. K. K. ;
Hadziyannis, S. ;
Jin, R. ;
Piratvisuth, T. ;
Germanidis, G. ;
Yurdaydin, C. ;
Diago, M. ;
Gurel, S. ;
Lai, M-Y ;
Brunetto, M. R. ;
Farci, P. ;
Popescu, M. ;
McCloud, P. .
GUT, 2007, 56 (05) :699-705
[6]  
Buster EHCJ, 2008, NETH J MED, V66, P292
[7]   The impact of biologic response modifiers on hepatitis B virus infection [J].
Carroll, Matthew B. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (04) :533-544
[8]   A randomized, controlled trial of combination therapy for chronic hepatitis B:: Comparing pegylated interferon-α2b and lamivudine with lamivudine alone [J].
Chan, HLY ;
Leung, NWY ;
Hui, AY ;
Wong, VWS ;
Liew, CT ;
Chim, AML ;
Chan, FKL ;
Hung, LCT ;
Lee, YT ;
Tam, JSL ;
Lam, CWK ;
Sung, JJY .
ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) :240-250
[9]   Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients [J].
Chen, Chien-Hung ;
Lee, Chuan-Mo ;
Hung, Chao-Hung ;
Wang, Jing-Houng ;
Hu, Tsung-Hui ;
Changchien, Chi-Sin ;
Lu, Sheng-Nan .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (03) :461-468
[10]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
123456789